Translational Potential of Non-coding RNAs for Cardiovascular Disease
Abstract
Heart failure is the end result of a variety of cardiovascular disease states. Heart failure remains a challenge to treat, and the incidence continues to rise with an aging population, and increasing rates of diabetes and obesity. Non-coding RNAs, once considered as "junk DNA", have emerged as powerful transcriptional regulators and potential therapeutic targets for the treatment of heart failure. Different classes of non-coding RNAs exist, including small non-coding RNAs, referred to as microRNAs, and long non-coding RNAs. Both microRNAs and long non-coding RNAs play a role in cardiac development as well as in the pathogenesis of cardiovascular disease, prompting many studies to investigate their role as potential therapeutic targets. Most studies manipulate miRNAs and lncRNAs of interest via antisense oligonucleotides; however, several challenges remain limiting their potential clinical value. As such, viral and non-viral delivery methods are being developed to achieve targeted delivery in vivo.
Read the paper
Related studies
- Regulation of nucleolus assembly by non-coding RNA polymerase II transcripts
- For a Healthy Histone Code, a Little SUMO in the Tail Keeps the Acetyl Away
- Discovering a binary CTCF code with a little help from BORIS
- Article Commentary: Stabilizing the Code–-Methods to Preserve RNA Prove Their Worth
- Foreword to the Special Issue for the RINTC (The Implicit Seismic Risk of Code-Conforming Structures) Project
- Commentary: Promoting Health and Well-being in Pediatric Primary Care Settings: Using Health and Behavior Codes at Routine Well-child Visits
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.